Abstract: A biological sample, for example blood, serum, or plasma, is evaluated for the presence of anti-Zika virus (ZIKV) IgM- and IgG antibodies specific for ZIKV nonstructural protein 1 (NS1) by measuring the signal intensities of such antibodies in an immunoassay of the sample. Subjects are scored as being positive or negative for ZIKV infection based on the combined results of such determinations.

Abstract: A method includes performing a nucleic acid amplification of a nucleic acid sample using a detection probe, wherein the nucleic acid amplification occurs over one or more interrogation periods, and, from the nucleic acid amplification, acquiring amplification data that indicates an amount of nucleic acid present for each of the one or more interrogation periods. The method also includes, based on the amplification data, determining a crosstalk correction value associated with a spectral neighbor to the probe to reduce spectral crosstalk from the spectral neighbor; and applying the crosstalk correction value to amplification data collected from multiplex nucleic acid amplifications of nucleic acid samples.

Abstract: The present invention relates to a method for detecting Zika vims (ZIKV) infection in a biological sample from a subject. The method comprises testing the sample for IgM- and IgG-ZIKV NSI antibodies and determining the ZIKV IgM and ZIKV IgG signal intensities; and scoring the sample as positive or negative for ZIKV infection based on the combined results of such determinations. The biological sample is preferably blood, serum, plasma, cerebrospinal fluid, saliva or urine.